Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03573648
Title Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

estrogen-receptor positive breast cancer

Therapies

Leuprolide

Avelumab + Palbociclib + Tamoxifen

Avelumab + Tamoxifen

Leuprolide + Palbociclib

Avelumab + Leuprolide

Avelumab + Leuprolide + Palbociclib

Tamoxifen

Goserelin

Palbociclib + Tamoxifen

Avelumab + Goserelin

Goserelin + Palbociclib

Avelumab + Goserelin + Palbociclib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.